For decades, intra-arterial treatment (IAT) was considered a potentially valuable expansion of the therapeutic options for acute ischemic stroke. However, until the end of 2014, IAT with mechanical devices had not been proven effective in randomized clinical trials.
1-3 The Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands (MR CLEAN) trial was a randomized clinical trial of IAT for acute ischemic stroke in patients with a confirmed intracranial occlusion in the anterior cerebral circulation who could be treated within 6 hours of onset. The intervention contrast was IAT vs no IAT against a background of best medical care, including intravenous alteplase if indicated. The trial demonstrated a shift in the distribution of functional outcomes on the modified Rankin Scale (mRS) in favor of the intervention, and this finding was consistent in almost all subgroup analyses.
4 With IAT, the rate of patients achieving independence (mRS score, 0-2) increased from 19% to 33%. Four published trials
5-8 and 2 unpublished trials
9,10 confirmed the effect of IAT.